Вы находитесь на странице: 1из 45

WSAVA

(2010)
( )

WSAVA (2010)
(VGG)
(WSAVA).
VGG, :
M.J. Day, M.C. Horzinek, R.D. Schultz
Guidelines for the Vaccination of Dogs and Cats (2010)
: Journal of Small Animal Practice, 2010, v. 51, pp. 338-356;
WSAVA: http://www.wsava.org/guidelines/vaccination-guidelines.
.. , .. (2014 .)
, . ..




WSAVA (2010)
1.
2.
3.
4.
5.
6.
7.
8.
9. I.
( )
10. II.
11. III.
( )
, VGG
( WSAVA)

( )

2
3
4
5
5
6
7
8
8
13
15
16

24

35
36



(WSAVA) WSAVA
.
. ,
, ,
(DOI),
.

WSAVA, .
.
,
.
.. , ..


/
/
/
/
/

;
;
;
;
;

AC (Artificial Colostrum) ;
AHCh (Annual Health Check) ;
ALB (Avirulent Live Bacterin) vaccines
;
CAV (Canine AdenoVirus) ;
CCV (Canine CoronaVirus) ;
CDV (Canine Distemper Virus) ;
CIV (Canine Influenza Virus) ;
CPiV (Canine Parainfluenza Virus) ;
CPV-2 (Canine ParvoVirus type 2) 2;
DOI (Duration Of Immunity) ;
FAQs (Frequently Asked Questions) ;
FCoV (Feline CoronaVirus) ;
FCV (Feline CaliciVirus) ;
FeLV (Feline Leukemia Virus) ;
FHV-1 (Feline HerpesVirus-1) -1;
FIP (Feline Infectious Peritonitis) ;
FISS (Feline Injection Site Sarcoma) ;
FIV (Feline Immunodeficiency Virus) ;
FPV (Feline ParvoVirus) ;
KB (Killed Bacterin) vaccines ()
;
KV (Killed Virus) vaccines () ;
MDA (Maternally Derived Antibody) ;
MLV (Modified Live Virus) vaccines
;
OspA (Outer surface protein A) A;
PETS (Pet Travel Scheme) ;
RV (Rabies Virus) ;
VGG (Vaccination Guidelines Group) ,
;
WSAVA (World Small Animal Veterinary Association)
.

Rabies Virus (RV)

Bb

Bordetella bronchiseptica

F TM

Trichophyton spp.
Microsporum spp.

( )

Canine Distemper Virus (CDV)

H A

Canine AdenoVirus
(CAV-1 CAV-2)

Canine ParvoVirus (CPV-2)

Canine CoronaVirus (CCV)

Pi

Canine Parainfluenza Virus (CPiV)

Leptospira spp.

Feline ParvoVirus (FPV)


Panleukopenia Virus

R H

Feline HerpesVirus (FHV-1)

Feline CaliciVirus (FCV)

Ch

Chlamydia spp.
Chlamydophila spp.

WSAVA (2010)
1.
VGG
(WSAVA) 2006 ,
() .
VGG 2007 ( ).
, , -2007
,
. , 2010 ,
-2010.
( VGG) ,
( )
.
, .

, (herd immunity),
.
VGG (core),
(non-core), (not recommended).
(core)
( ,
).
:
(CDV);
(CAV);
2 (CPV-2).
:
(FPV);
(FCV);
-1 (FHV-1).
(RV) ,
.
(MDA)
.
MDA ,
VGG 3 ,
14-16 .
,
(core) 16 .
, .
(core) /
12 ( ).
, 1 3 , (DOI)
( ).
5

(non-core)
,
.
, (non-core),
(AHCh), DOI
1 .
, VGG (not recommended)
, .
,
(minority products), .
, ,
VGG . ,
(core)
. ,
1 (. 2, 4).
VGG
.
VGG
.
-2010:
(core)
, (non-core)
.

2.
VGG ,
. VGG
2009 2007 ,
.
( )
WSAVA.
, -2007
, VGG 70 -
WSAVA . :
1. WSAVA 2007
?
2. -2007
?
3.
?
4. , 2007 ?
5. - WSAVA
?
6

,
, VGG .
27 .1 ,
. 12 27
-2007 .
13 27 , VGG 6
. 14 , , 12 2007 , .
,
VGG.
, .
.
2010 :
1. .
2. , .
3. (CIV),
(leishmaniosis) (malignant melanoma).
4. ,
(FHV-1 FCV),
(FeLV).
5. .
6.
2c (CPV-2c).
7. (fact sheet) .
8. (FAQs).
, -2007
.
9. ,
.
.

3.

(data sheet), ,
.
,
(). DOI
, DOI
.
DOI 1 , .

( 3 ) (,
, DOI). (core)
DOI 3 .

, ( ).

1 3 ,
DOI 1 .
, ,
(
20 ). ,
( !) (
off-label use2- ).

4.
VGG :
, ?
:
(core)
,
. ,
30-50 % .
, (herd immunity):
,
.
,
.
, .

5.


VGG 1. (core)
, .
.

, ,
. (non-core)
.
12
(MDA)
. ,
, 8-12 . MDA ,
,
.
MDA 12 . ,
VGG 8-9 , 3-4 ,
14 16 . 2- 3-
.
Off-label use ; ,
.
2

( ) 10 ,
. VGG 14-16 , .
(
)
. (
T- B-)
, .
- MDA
(, , ).
12
. ,
() .

,
(MLV-vaccines) (core)
.
12 () ,
VGG , 1
3 . (core)
(non-core) ( ). ,
Leptospira, Bordetella, Borrelia (Lyme disease)
(CPiV) .
VGG ,
( ),
(core + non-core),
.
(
12 )
,
. (
),
.
,
.

CDV, CPV-2,
CAV-1 . (
) ( -).
, 2
() , / (
).

. - ,
(non-responder).3

.
- :

:
1. MDA .
14-16 98
% .
2. . ,
, , , , .
3. . ,
80- CPV-2
. ,
non-responder.
CPV-2
, .
non-responder,
CPV-2
/, (PETS).

Non-responder , .

10

DOI
(core) .
/
(memory effector B cells).
. (core)

, (non-core) (Leptospira
CPiV). , /
(core) .
, CDV, CPV-2, CAV-1 CAV2 3 . /
, - .

, .
, VGG ,
, .

,
, / (viral load)
.
( ,
) ,
.
- / .
( ) ,
.

. ,

, / ,
(
).
,
( ,
, ).
( ), ( )
, , ( )
.

CDV. (
,
.)
(
), .
.
11

FPV CPV-2 ,
.
/ 24-48
. .

() .
, .
.
VGG
.

VGG ,
(
).
(CIV)
2009 . Influenza A
subtype H3N8 ,
. 6- 2-4 ,
, . 7
2- . (non-core).
(leishmaniosis), GP63
( fucose mannose ligand) Leishmania donovani ,
,
, . /
, Leishmania .

,
1,3 % .
,
()
, .
(core) , .
(malignant
melanoma) 2007
2010. - ( ,
)
. ,
,
. II-IV
90 389 .4 .

P.J. Bergman, M.A. Camps-Palau, J.A. McKnight, N.F. Leibman, D.M. Craft, C. Leung, J. Liao, I. Riviere, M.
Sadelain, A.E. Hohenhaus, P. Gregor, A.N. Houghton, M.A. Perales and J.D. Wolchok. Development of a
xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Centre. Vaccine,
2006, v. 24, pp. 4582-4585.

12

6.


(core),
(non-core) (not recommended) 3.
(core) , FCV FHV-1
, FPV. (core)
, .
FCV
,
. FHV-1 ,
,
() .
.
,

. VGG FCV
FHV-1, , .

. VGG FeLV
(non-core)
.
12
,
(MDA). ,
, /
, . ,
MDA , ,
8-12 .
8-9 3-4 .
MDA , VGG
14-16 . ,
(core) 3 : 8-9 , 3-4 14-16
.

( )
, 12
. ,
.
1 3 .

(core) 1 .
(core) (MLV-vaccines)
- .
(core) (noncore) ( ). Chlamydophila Bordetella
.
13

VGG ,
( ),
(core + non-core),
(core)
(non-core) .
(
12 )
,
.
( ),
.
,
.

20 ,
(FISS)
FeLV. FISS
( / ) . -

().

FeLV ,
FISS . FeLV
,
. FISS (1990-1996) (1997-2006)
, FISS
, ( !)
. ,
. ,

.
.
FISS :
.
( ) ( ),
, .
(
)
.
(. ) ,
FISS ,
.
.
,
, .

.
VGG FISS.
14

( Prof. Jolle Kirpensteijn and the Multimedia Department of the


University of Utrecht)


. FPV

CPV . FCV FHV-1
VGG.
FIV
FIV.

7. 5

.
, (
).
2 4. ,
(core) (
), .
(core)
FCV FHV-1 .
VGG () .
(core)
(non-core)
.

, . VGG

.

( ).
5

15

8.

,
(core) 1 3
, .
VGG , (non-core)
, .

, , ,
( ),
( ) .
( ) .
, .
, ,
.
, ,
, (core) .
,
(core)
. ,
,
. , ,
, PETS / (0,5 /).

;
; , ,
; ; , .
, (off-label use),
.

) .
6 ,
.
, (), ,
( ).
()
, , .
. ,
- ,
!

( ).

16

1. WSAVA .

2
Canine Parvovirus-2 (CPV-2);
(MLV),
7

Canine Distemper Virus (CDV);
(MLV),

rCDV,

-2
Canine Adenovirus-2 (CAV-2);
(MLV),

CAV-2;
(MLV),

CPV-2;
(KV),

-1
Canine Adenovirus-1 (CAV-1);

(MLV or KV),


Rabies virus (RV);
(KV),



( 16 )
8-9 ,
3-4
14-16-
.



( 16 )


2-
3-4 ,
1
.


1 ,
,
3 .


(core) .


CAV-1.
,
(MLV).
,
(MLV) CAV-2.

1
3- .
*

,
2-4
.

1
.



DOI
1 3 .


.

(core) ,
,
.

/ / , . ,
, .

17


Parainfluenza Virus (CPiV);
(MLV),

8-9 ,
3-4
14-16-
.



2-
3-4 ,
1
.

CPiV
(MLV),

3-
,
3-4
.

2 34 .

Bordetella bronchiseptica
(ALB),

1
3-
.

2-4
.
6-8
10-12
.

2
2-4 .

:
12
,


()
(core)
,
2-4
.

2
2-4 .


,

.

Bordetella bronchiseptica
(KB),

Bordetella bronchiseptica

,
Borrelia burgdorferi (Lyme borreliosis);
(KB),

Borrelia burgdorferi (rLyme borreliosis);


(
A [OspA]),

18

1 ,
,
CPiV
CPiV

(non-core)
,
.
1 ,
.

(non-core) .
(MLV)
CPiV , ,

.

(non-core) .

Bordetella bronchiseptica.

() .
(non-core) .
CPiV.


(3-10 ) ,
.
(non-core) .
(ALB)
(KB)

.
(non-core) .
VGG
12

() (core)
.

(,
) ,
.

Leptospira interrogans
(
canicola, icterohaemorrhagiae);
(KB),

(
grippotyphosa pomona)

12-16
,


()
(core)
,
3-4 .

2
3-4 .


Canine influenza virus (CIV);
(KV)
,

2 2-4


6 .

2
2-4 .


Canine Coronavirus (CCV);

(MLV or KV),

(non-core) .

,
,
,
.
12-16 ,
3-4 , 9-12
,
.

,

.

.

,
,
.


.
(non-core) .
8 .

,
(,
, ).
(not recommended)
.
CCV
.

, (2010 ) .

19

2. WSAVA .


CDV + CAV-2 + CPV-2
(MLV)
CPiV
rCDV + CAV-2 + CPV-2
CDV (rCDV) +
(MLV)
CPiV
/
/

Bordetella bronchiseptica + CPiV
(ALB)
+ (MLV)

.
.
Bordetella bronchiseptica
(KB)

,



( 16 )

.
2-
16-
,
.
:
CDV- / CPV-,
CDV
4- .
1
3- .
6 ,
6-

.

.
2-4 .



( 16 )


. 2
.

, 6-
.
.
4 (
).
,
.

2
2-4 .

(ALB)
,

6 . , 1 .

2
2-4 .


16 ,


.

,
.
. ,
,
.
, ,
.

, ,
.


Canine influenza virus (CIV);
(KV)
,

6
, 2-4
.

2
2-4 .


Rabies virus (RV);
(KV),

2 2-4
,

.

,
,

.

20

3. WSAVA .


Panleukopenia Virus (FPV);
(MLV),

FPV
(MLV)
,

FPV
(MLV)
,
-1
Feline Herpesvirus-1 (FHV-1);
(MLV)
,

FHV-1
(KV)
,

Feline calicivirus (FCV);
(MLV)
,

FCV
(KV)
,

Rabies virus (RV);
(
) ,

RV ( DOI 1, 3 4 );
(KV)
,

( 16 )
8-9

3-4
16-

.



( 16 )
2
3-4 .

8-9

3-4
16-

.

2
3-4 .

1

,
3 .

8
, 1
.

2
12 .


12 ,
1 .

2
12 .


DOI
.

21

1

,
1 3 .

(core) .

,
FeLV / FIV.
,

,
,
.

.
(core) .
FHV-1 FCV
,
-
(, FPV).



.

(core) ,
,
.


Feline Leukemia Virus (FeLV);
(
) ,


FeLV
(KV)
,
FeLV
()
,

Feline Immunodeficiency Virus (FIV);
(KV)
,

2
.
8 ,

3-4 .

2
3-4 .


1

,
1 3


.

(non-core) .

FeLV.

.

3 :
8
, 2

2-3 .

3 :

2-3
.


1

,



.


Feline Infectious Peritonitis (FIP);
(MLV)
,

16

3-4 .

2
3-4 .

Chlamydophila felis
(ALB)
,
Chlamydophila felis
(KB)
,


9
3-4 .

2
3-4 .

(not recommended)
. ,
,

FIV, ,
,
FIV.
,
.
(not recommended)
.
, ,

,
.
.
(non-core) .




.


. ,

().

22

Bordetella bronchiseptica
(ALB)
,


8
.

(non-core) .

.
,


.

4. WSAVA .

FPV
FHV-1
FCV

( 16 )

4-6 .
2-4 16-
,
.
(4 )
(2 )

.
,
, .


( 16 )

. 2-4
, .

,
,
.
VGG .
RV

.
FPV,
, . ,

FCV/FHV-1 ,
(48 ).
,
FCV/FHV-1 ,
.

, ,
.

VGG
:
Crotalus atrox toxoid (rattlesnake vaccine) ( );
Porphyromonas sp. (periodontal disease vaccine) ;
Babesia vaccine (soluble parasite antigen from B. canis in saponin) ;
Babesia vaccine (soluble parasite antigen from B. canis canis and B. canis rossi in saponin) ;
Canine herpesvirus vaccine ;
Giardia lamblia (, ) ( 2007 ) .

:
Giardia lamblia (, ) ( 2007 ) .

23

10. II.
,
1. (MLV) ,
,
?
, (MLV) ,
.
,
.
. , ,
. !
() ( CDV
) .

. ,
CDV, .
2.
?
. - ,
, . ,
( CDV
), ,
CDV.
CDV, 16 .
3. -
(MDA) ,
(MLV) CDV?
() CDV
4 , (MLV). ,
, .
4. (MDA)
(MLV), ?
, (MDA)
(MLV),
() . ,
,
. , .
(MVL)
MDA 1 . -
2 , (
).
16- .
5. ,
, (MLV)
, 2 ,
10- . ?
24

VGG ,
.
, , ,
.
VGG
. VGG,
10
. VGG -
16 , , .
, ,
.
6. ,
( ,

)?
, .
() , FCV
FHV-1, .
FCV FHV-1 ,
.

Bordetella .


.
, ( )
.
(
) . ,
,
( IgA ). ,
, IgA
(, I ),
.
7. (core)
, ?
,
, .
,
:
CDV
(MLV), ( ).
.
( MDA
).
CPV-2 FPV 3 ,
(MLV) , 5
. CPV-2 FPV
2-3 .
25

(MLV) CAV-2
CAV-1 5-7 .
CAV-2 CAV-1
2- , .
CAV-1 CAV-2.
FCV FHV-1 .
7-14 .
8. (core)
/ /?
(core)
:
, (MLV)
CDV, CPV-2 CAV-2, 98 %
. ,
.
(MLV)
FPV , ,
98 % .
FCV FHV-1 ,
( ).
60-70 % .
, ,
, , .
9. CDV CPV-2 (
), ?
, ,
CDV CPV-2
CDV CPV-2.
10. CPV-2
CPV-2c? ?
CPV-2, ,
,
2a, 2b 2c.
, 4- .
11. (CPV-2 FPV)
?
CPV FPV , .
,
(/, /).
12. - CPV-2
(MDA) , ?
. , /
( ), ( 2
).

26

13.
?
.
CDV, CPV-2 CAV-2 ; FPV ;
. , ,
.
.
14. Leptospira, ,
2 , (, 4-
, )?
, ,
, Leptospira,
(
).

canicola, icterohaemorrhagiae, pomona grippotyphosa,
4- .
.
15. Leptospira
( ) ,
?
. Leptospira spp. 3-12
70 %.
, ,
6 .

. ,
1 .
6-9 .
16.
(, , )
?
. 2- FeLV ( ,
, ), 8 2-4
. .
6- ,
, 2-6
.
17.
FeLV , 1 3 ?
FeLV
( 2-
, 12 ) FeLV
1 3 .
(FISS).

27

18. FIV?
-
( )
, .
FIV 2 (A D),
. FIV.
,
( , FIV,
).
19. FIV
(FIV)?
. FIV,

.
20.
- , (CIV)?
. , ,
3
. CIV ,
(Equine Influenza Virus, H3N8). CIV
.
21. (CIV)?
,
, H3N8.
, 2- 2-4 .
(DOI)
.
22. / ,

,
,
/ / ?
. :
;
;
;
.
23. 9 ?
. , .

,
( )
.
9

28

,
24. ?
, .
25. (
)?
, (
).
26.
, ?
, (1,0 )
, .
27.
( , ) (-) ?

,
.
28. ?
,
, . ,
.
29. ?
.
CDV FPV
.
30.

(core) ?

/ .
2
,
(core) .
31. (
)
( )?
,
(MLV)
. ()
- .
.
32.
?
2 .
29

33. ?
, , . ,
, 1 2 .
34.
?

14-16 .
35. ,
?
(RV), (MLV) .
()
, . (MLV) ,
( ) (KV) .
36.
Bordetella ?
.
(, ) .
37. () Bordetella
?
, Bordetella,
.
, .
38.
FCV/FHV-1?
(MLV)
FCV/FHV-1 ( ),
.
39.
?
,
,
(, FCV).
40. (, )?
, ,
(MLV) .
41. ?
.
. , Leptospira
.
,
Leptospira ,
.

30

42. ?
?
16-
(MLV) (core) (CDV, CPV-2, CAV-2 ;
FPV, FCV, FHV-1 ) .
. ,
, 50 % /
25 % / .
,
, 75 % .
43. , 1 ,
(, Leptospira FeLV),
6- ?
. 1 , ,
6 , .
( Leptospira FeLV) ,
.
6 , : 2 2-6 ,
.
44. (MLV)
?
( CDV FHV-1)
2-3 ,
(CPV, FPV). VGG
(MLV) 1-2 .
45. (
2-4 ),
(DOI) (core) ( 7 9 CDV, CPV-2, CAV2; 7 FPV, FCV, FHV-1)?
. (MLV)
,
(MDA). DOI
(core) , 1 .
,
.
46. , FeLV / FIV?
, FeLV FIV,
, .
(MLV), (KV)
(core) FPV, FCV FHV-1, FeLV
FIV. ,

, .

31

47. ?
( )
.
, FeLV .

.
(FISS) ,
VGG .
, , .

,
.
48. ?
. ( E
Se) .

.
49. , ?
( , MDA)
, , ,
/ . 95 % /
,
72 (3 ) .
50. ,
(MDA), ?
, MDA,
. 46 (MLV) (core) .
(MLV)
2-
, . -
,
.
51. (core)
?
3- ,
(AC).
50 % (, EsbilacTM), 50 %
. ,
.
(, ) 3-
,
(/ ), (/).
/, 3-10 2
3- .

32

,
52. - (over-vaccinating) (,
,
)?
. ,
. (KB)
, .
53. ,
?
, ,
I , (
). ,
(KB) Leptospira, Bordetella, Borrelia
Chlamydophila , (MLV).
54. ,
- (, ,
, ,
)?
-
(core) , .
( / CDV, CPV-2, FPV)
. (noncore) , , (KB) Leptospira
Bordetella . ,


.
,
.
, (,
, ).

. 24
, I
. (II, III, IV)
( ).
55. ?
,
, ,
, , .
56. ?
-
.
, . ,

. ,

.
33


.
. ,
, , 38
10.000 ( 3- ), 52 10.000 (
30- ). , ,
.
, .
57. ,
?
, , .
(non-responder)
(, CPV FPV), , , .
, (,
Bordetella bronchiseptica).
58.
(core) ?
. (core)
, (MLV) CDV
CAV-2, . 3
.
(MLV-CDV MLV-CAV-2), .
59. , ,
(core) ( CDV, CPV-2, CAV-2)?
:
, (MLV) CDV CPV-2,
(MLV) CAV-2 ,
( B. bronchiseptica
CPiV);
, (MLV) CPV-2 CAV-2,
( ) CDV.
60. ,
Leptospira ,
( 1 ), ?
Leptospira ( 1 )
IgG-,
4 .

34

, VGG
( http://www.wsava.org/guidelines/vaccination-guidelines)

2010 (PDF)
2007 (PDF)
2007 (PDF)
2007 (PDF)
(PDF)


2013 (PDF)

2010 (PDF)

35


( )

(DOI)


10
/


VGG
,

Intervet (MSD Animal Health)


Nobivac Rabies
(KV)

RV

1 3

(core) .

8
3 .
.

CDV
CAV-2
CPV
(+ CPiV DHPPi)

12

L. canicola
L. icterohaemorrhagiae
CPiV
Bordetella
bronchiseptica

12

(core) ( DHPPi
(noncore) CPiV).

12
DHP ( DHPPi) .
Rabies Lepto,
2-4
Lepto.
(Diluent)
DHP ( DHPPi)
Rabies Lepto.
(non-core) .

12

Nobivac
DHP (DHPPi)
(MLV)

Lepto11
(KB)
KC (kennel cough)
( ),

1 3

(non-core) .

,
0,51 . 2- ,

.

2- / ( ) , 12 .
Leptospira spp. : ( ), , ,
, + . : , .
10
11

36

Piro

Babesia canis canis


Babesia canis rossi12


6
1 6

VGG
(minority products).


6
( 6-

3-6 ). 1
.
, 2
.

FPV
FCV
FHV-1

12

, 3

(core) .
Rabies .

Nobivac
Tricat Trio
(MLV)

Forcat
( )

Bb
(ALB),

FPV
FCV
FHV-1
Chlamidia
Bordetella
bronchiseptica

12

1 3

12

(core
+ non-core) .
(non-core) .

.
4- .

.
72 (3 ).

Merial

(KV)

RV

12

3 ,
1

12

Babesia canis rossi


B. canis canis.

(core) .
.


.

37

(MLV)
DHPPi2L (DHPPi2LR)13

13

Pi2

CPV

:
CDV
CAV-2
CPV
CPiV-2
:
L. canicola
L. icterohaemorrhagiae
(+ RV DHPPi2LR)
:
CDV
CAV-2
CPV
:
RV
L. canicola
L. icterohaemorrhagiae
Babesia canis

12

1 2

12

12

(core
+ non-core) .

12 ,
1 .


.

12

6 12

VGG
(minority products).

80 %
.

3-4 5-
.

2- .

38

(core) .

(core
+ non-core) .


.

Purevax RCP (RCPCh)


Purevax FeLV14
(
)

:
FPV

:
FCV
FHV-1
:
FPV

12

(core) .


.

12

12

(core) .

3- ,
1 .
,
, ,


Merial.
(core
+ non-core) .

,
.

:
FCV
FHV-1
RV
:
FPV
FHV
(+ Chlamydophila felis
RCPCh)
:
FCV
FeLV

3 FPV

12

FeLV : , + . : , , , .
: .
14

39

(non-core) .



( ).
.
78 %.
Purevax ,
.

Zoetis (Pfizer)
3
(KV)

RV

12


(
3- ,
1
)

:
1 3 ,

(core) .
.

70 %-
.15

(
)


5/L

5
:
CDV
CAV-2
CPV
CPiV
C1
:
L. canicola
L. icterohaemorrhagiae
DA2Pi
:
CDV
CAV-2
CPiV

12

(core
+ non-core) .

70 %-
.

12

(core
+ non-core) .

70 %-
.

CPV-L
:
CPV ( 2, 2a, 2b, 2c)
:
L. canicola
L. icterohaemorrhagiae
15

VGG.

40

5/4L

5CVK/4L

DA2PPv
:
CDV
CAV-2
CPV
CPiV
LCIGP
:
L. canicola
L. icterohaemorrhagiae
L. grippotyphosa
L. pomona
DA2PPv
:
CDV
CAV-2
CPV
CPiV

12

(core
+ non-core) .

70 %-
.


.

12

, (core +
non-core)
(not recommended CCV) .

70 %-
.


.

(core
+ non-core) .

70 %-
.
(core
+ non-core) .


8- .

.

CCV-LCIGP
:
CCV
L. canicola
L. icterohaemorrhagiae
L. grippotyphosa
L. pomona


4
( )

FPV
FCV
FHV-1
Chlamidia psittacci

12

4
( )

FPV
FCV
FHV-1
Chlamidia psittacci

12

41

FIP16

FCoV

12

(not recommended)
.

.17


/ FCoV.

( ) 16-
.

FIP : ( - ), + . .
, 31 ,
( ) . , IgA.
16
17

42

(MSD Animal Health)


Nobivac18
: DHP (+ Pi)
( ,
, ,

( DHPPi))

4-6 .

Puppy DP

(
Bordetella
bronchiseptica)

Lepto

KC (/)

Rabies

DHP/DHPPi

8-9 .

(X)

12 .

3- ,
, .
(X)
3-

18

VGG.

43

(MSD Animal Health)


Nobivac19

:
FCV, FHV-1, FPV
(, 1,
)

Tricat Trio

+ Bb
(Bordetella
bronchiseptica)

+ C. felis
()

Bb (/)

Forcat

Rabies

4 .

6 .

8-9 .

(X)

12 .

16 .

(XX)

(XX)

(X)
3- ;
(XX) MDA (
9- )

19

VGG.

44